Life sciences tools stocks are entering a more selective recovery phase. Rather than being driven by one blockbuster product cycle, the group is benefiting from gradually improving biotech funding, renewed dealmaking, and steadier demand from biopharma and adjacent research markets. Investors are increasingly separating companies with durable consumables, service revenue, and high-value workflows from instrument makers that remain more exposed to laboratory capital-spending timing. Agilent’s better-than-expected quarterly results and raised guidance have added to the view that demand is improving as biotech activity normalizes.
The long-term case rests on several durable forces: rising research intensity, the need to replenish aging drug pipelines, greater outsourcing of research and manufacturing, and the adoption of automation and AI-enabled workflows. Within the theme, however, exposure varies considerably. Genomics, proteomics, cell and gene therapy, diagnostics, and bioprocessing can provide more specialized growth avenues, while large analytical instruments and laboratory platforms may respond more sharply to funding and capex cycles. That makes business mix and execution especially important in this recovery.
The following countdown moves from #7 to #1. It includes businesses ranging from specialized genomics and proteomics platforms to broad laboratory, analytical, bioprocessing, and diagnostic franchises. The ordering emphasizes depth of exposure to life sciences tools first, followed by business fundamentals, profitability, growth, valuation, and recent earnings execution.
Our screen uses US-listed companies with market capitalization above $500 million as the starting universe, then evaluates how directly each business participates in life sciences tools and services. The ranking gives priority to depth of thematic exposure before considering margins, growth, valuation, analyst expectations, and earnings consistency. The list is presented in countdown order, so the best pick is reserved for #1 at the end. The quality grade is our composite assessment, while the analyst consensus and target reflect the supplied market estimates.
What they do. The company develops and sells instruments, consumables, assays, and services for biomedical researchers through its Proteomics and Genomics segments. Its platforms include SomaScan for measuring proteins, CyTOF for multiplexed cellular analysis, Hyperion for spatial biology, and Biomark X9 for high-throughput quantitative PCR. That combination gives Standard BioTools a specialized technology position, but its model still depends on converting instrument placements into follow-on consumables and research demand.
Why it fits. Standard BioTools is one of the most direct thematic exposures in the group because its products sit squarely in genomics, proteomics, spatial biology, and multiplexed research workflows. Those are high-value areas highlighted by the sector recovery, particularly as researchers seek more information from each sample and as drug-development programs require deeper biological characterization. The trade-off is that this focused exposure comes with less financial resilience than the larger diversified names in the ranking.
Numbers that matter. Revenue was $84.43 million, with a 52.2% gross margin, but the operating margin was negative 41.75% and EBITDA was negative $38.09 million. Revenue declined 0.9% year over year, while trailing EPS was negative $0.09 and next-year EPS is estimated at negative $0.16. The quoted P/E was negative 9.19, and the composite valuation assessment was unfavorable despite a strong price-to-book component, underscoring the challenge of valuing a loss-making platform company.
Recent momentum. The latest listed quarter produced EPS of negative $0.06 versus an estimated negative $0.01, a negative 500.0% surprise, following a negative 66.7% surprise in the prior listed quarter. Standard BioTools has beaten estimates in only 1 of 8 quarters. The analyst breakdown shows 1 Hold and no listed Buy or Sell ratings, leaving the $1.35 average target as a relatively limited signal of conviction.
What they do. The company provides health sciences instruments, reagents, software, subscriptions, imaging and detection technologies, and related services, alongside diagnostic instruments and assay platforms. Revvity serves biopharma companies, laboratories, academic institutions, public health agencies, and healthcare organizations, with products spanning genetic screening, infectious disease testing, oncology, immunodiagnostics, and drug discovery. Its mix of consumables, software, subscriptions, and service offerings gives it broader revenue channels than a pure instrument manufacturer.
Why it fits. Revvity connects the life sciences tools theme to both research and diagnostics. Its genomic workflow technologies, next-generation sequencing support, Alpha and BioLegend offerings, and early-detection platforms provide exposure to genomics, proteomics, cellular analysis, and clinical testing. That breadth should allow the company to participate in a recovery across biopharma research and laboratory testing rather than depending on one workflow alone.
Numbers that matter. Revenue was $2.94 billion, with a 55.9% gross margin, 16.35% operating margin, and 8.61% net margin. Revenue grew 4.3% year over year, while earnings growth was 37.8%; trailing EPS was $2.23 and next-year EPS is estimated at $5.9603. The core trailing P/E was 70.9641 compared with a forward P/E of 26.5957, so the valuation depends heavily on the expected earnings improvement rather than current-period profits alone.
Recent momentum. Revvity’s latest listed quarter delivered EPS of $1.38 versus an estimate of $1.29, a 7.0% beat, after a 14.6% beat in the prior quarter. The company has exceeded estimates in all 8 listed quarters, providing one of the strongest execution records in the group. Analysts show 11 Holds and 1 Sell, with no listed Buy count, which supports a measured rather than aggressive consensus despite the $171.07 average target.
Market cap: $11.4B · Quality grade: B · Analyst consensus: Hold (avg target $70.50)
What they do. The company develops and manufactures life sciences reagents, instruments, and services for research, diagnostics, and bioprocessing. Its Protein Sciences segment sells cytokines, growth factors, antibodies, cell-selection technologies, protein-analysis instruments, and immunoassays, while Diagnostics and Spatial Biology supplies diagnostic assays, molecular controls, tissue-based in-situ hybridization products, and oncology and genetic kits. This creates a mix of research consumables, analytical instruments, and specialized diagnostics.
Why it fits. Bio-Techne has unusually direct exposure to protein science, cell and gene therapy research, bioprocessing, and spatial biology. Cytokines, growth factors, antibodies, automated protein analysis, and tissue-based assays all support workflows that become more valuable as biopharma programs move toward more complex biological targets. Its combination of reagents and specialized platforms also fits the market’s preference for consumables and higher-value research applications.
Numbers that matter. Revenue was $1.23 billion, with a 66.2% gross margin, 13.44% operating margin, and 14.0% net margin. Revenue increased 4.6% year over year, but earnings growth declined 25.0%; trailing EPS was $1.09 and next-year EPS is estimated at $1.70. The core trailing P/E was 66.8073 and forward P/E was 35.7143, making valuation a material constraint even if earnings recover.
Recent momentum. The latest listed quarter produced EPS of $0.36 versus an estimate of $0.40, a negative 10.0% surprise. That result followed a 6.5% beat in the prior quarter, and Bio-Techne has beaten estimates in 5 of 8 listed quarters. The analyst consensus is Hold, based on 12 Holds with no listed Buy or Sell count, while the average target is $70.50.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. The company designs, manufactures, sells, and services liquid chromatography and mass spectrometry systems, columns, and other consumables. It also provides thermal analysis, rheometry, calorimetry, and software products that interface with its instruments and other laboratory systems. Waters serves pharmaceutical, clinical, biochemical, academic, environmental, and industrial customers, generating revenue from instruments, recurring laboratory consumables, service, and software-enabled workflows.
Why it fits. Waters is a highly focused analytical-tools company whose chromatography and mass spectrometry technologies are central to drug discovery, development, clinical testing, protein analysis, and quality control. Its consumable columns and support products add a repeat-purchase component to an instrument-led business. The company therefore offers direct exposure to pharmaceutical research and manufacturing workflows, though its equipment orientation leaves it sensitive to laboratory capital budgets.
Numbers that matter. Revenue was $5.61 billion, with a 49.8% gross margin, 9.75% operating margin, and 1.76% net margin. Reported revenue growth was 120.9% year over year, while earnings growth was negative 67.2%; trailing EPS was $2.39 and next-year EPS is estimated at $16.5277. The core trailing P/E was 197.0293 versus a forward P/E of 28.3286, indicating that the valuation is primarily looking through the current earnings base.
Recent momentum. Waters reported latest listed-quarter EPS of $4.10 versus an estimate of $3.99, a 2.8% beat, and has exceeded estimates in all 8 listed quarters. The analyst breakdown includes 3 Buys, 4 Holds, and 1 Sell, producing a Buy consensus and a $503.29 average target. The consistent earnings record supports the recovery case, even as the modest latest surprise suggests expectations are already substantial.
What they do. The company provides application-focused solutions across life sciences, diagnostics, and applied chemistry. Its offerings include liquid chromatography and mass spectrometry, genomics and pathology products, contract development and manufacturing capabilities, laboratory software, automated sample preparation, consumables, service, maintenance, training, and compliance support. The Agilent CrossLab segment gives the company a meaningful service, software, and consumables layer alongside its instrument portfolio.
Why it fits. Agilent covers several of the theme’s most important workflows, including genomics, biomolecular analysis, pathology, diagnostics, chromatography, mass spectrometry, and laboratory informatics. CrossLab’s repairs, maintenance, software as a service, consumables, and workflow support can make the business less dependent on one-time instrument sales. Its recent demand improvement in biopharma, including the reported boost from GLP-1-related tool purchases, reinforces the company’s relevance to the current recovery narrative.
Numbers that matter. Revenue was $7.37 billion, with a 53.6% gross margin, 25.56% operating margin, and 19.53% net margin. Revenue grew 8.1% year over year and earnings grew 8.5%; trailing EPS was $5.01 and next-year EPS is estimated at $6.7195. The core trailing P/E was 35.505 and forward P/E was 26.6667. Return on equity was 20.97% and return on assets was 8.63%, among the stronger profitability measures in the group.
Recent momentum. Agilent’s latest completed listed quarter delivered EPS of $1.62 versus an estimate of $1.48, a 9.5% beat, following a 5.7% beat in the prior quarter. The company has beaten estimates in 5 of 7 listed quarters. Analysts show 3 Buys and 7 Holds with no listed Sell count, resulting in a Buy consensus and a $182.05 average target.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This November 2026 ranking starts with US-listed life sciences tools and services companies and applies a market-cap threshold above $500 million to the candidate universe. Companies are ordered first by the depth and directness of their exposure to the theme, including genomics, proteomics, diagnostics, analytical tools, bioprocessing, cell and gene therapy, and laboratory services. Business fundamentals then determine the placement: profitability, revenue and earnings growth, valuation, analyst consensus, and recent earnings execution all inform the final order. The article is refreshed monthly using the latest supplied financial and market data, while the countdown format keeps #1 as the final selection.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.